RNS Number : 5234Q
Shield Therapeutics PLC
29 June 2022

Shield Therapeutics plc
("Shield" or the "Company" or the "Group")

Notice of Results
Analyst and Investor Briefings

London, UK, 29 June 2022: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, will announce its final results for the year ended 31 December 2021 on Thursday 30 June 2022.

Analyst briefing
A briefing open to analysts will take place remotely via Zoom on Thursday 30 June 2022 at 13.30 (BST). If you would like the details of this call, please contact Walbrook PR on shield@walbrookpr.com.

Investor Briefing
CEO, Greg Madison, CFO, Hans-Peter Rudolf, and CMO, José Menoyo MD, will also be hosting a live online presentation relating to the final results via the Investor Meet Company platform at 16.30 (BST) on Thursday 30 June. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here:
https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor

Investors who already follow Shield on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards and via the Company's website.

For further information please contact:

Shield Therapeutics plc	www.shieldtherapeutics.com
Greg Madison, CEO	+44 (0) 191 511 8500
Hans-Peter Rudolf, CFO	
Nominated Adviser and Joint Broker	
Peel Hunt LLP	
James Steel/Christopher Golden	+44 (0)20 7418 8900
Joint Broker	
finnCap Ltd	
Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks	+44 (0)20 7220 0500
Financial PR & IR Advisor	
Walbrook PR	
Paul McManus/Lianne Applegarth/Alice Woodings	+44 (0)20 7933 8780 or shield@walbrookpr.com
Investor Contact (US Advisor)	

LifeSci Advisors, LLC
John Mullaly +1 617 429 3548 or jmullaly@lifesciadvisors.com

About Accrufer®/Feraccru®
Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com

About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.
Accrufer®/Feraccru® has patent coverage until the mid-2030s
Accrufer®/Feraccru® are registered trademarks of the Shield Group

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORBUGDLRDDDGDI